Rubenstein Public Relations Named Agency of Record for OS Therapies

Clinical-Stage Oncology Company Taps RPR to Drive Global Communications as Groundbreaking Cancer Immunotherapy Advances Toward Approval

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) --  Rubenstein Public Relations (RPR), a leading full-service communications firm, announces it has been named the Agency of Record for OS Therapies, Inc. (NYSE American: OSTX), the world leader in gene-edited, Listeria-based cancer immunotherapies.

Recently, OS Therapies announced that it has reached a critical point in achieving entry into the global market with access into the U.K national patient registry and UK Clinical Practice Research Datalink (CPRD) by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). This comes after OS Therapies was accepted into the US Food and Drug Administration’s (FDA) Project Orbis, where 29 MHRA-led oncology products have been approved.

“As OS Therapies works with global regulatory agencies and stakeholders to deliver our treatments safely to market, we also recognize we need to ensure the public knows about the groundbreaking work our team is undertaking in the fight against cancer,” said Paul Romness, MPH, Chairman & CEO of OS Therapies. “We are pleased to be working with Rubenstein Public Relations who has an extensive record of working with biotech, pharmaceutical and medtech organizations across a broad media landscape.”

RPR will develop and execute a comprehensive communications campaign to guide corporate messaging and brand positioning across U.S. and global markets.

About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The Company is the world leader in gene-edited, Listeria-based cancer immunotherapies. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 is designed to target two mutated extracellular epitopes and one mutated intracellular epitope of the HER2 oncogene, requiring only one of these three epitopes to be present in a tumor (or micro-metastasis) to trigger the desired immune response. OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and has received ODD, FTD and Advanced Therapy Medicinal Products (ATMP) from the European Medicines Agency.

The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma, demonstrating clinically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study and the overall survival (OS) secondary endpoint. The Company is seeking a Biologics License Application (BLA) from the U.S. FDA for OST-HER2 in osteosarcoma in 2026 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. The Company also anticipates receiving Conditional Marketing Authorization Applications from the U.K.'s Medicines and Healthcare products Regulatory Agency and the EMA for OST-HER2 in 2026. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 was previously conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. The Company has also completed dosing in a Phase 1 study of OST-504 for castration-resistant prostate cancer.

In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicon Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

About Rubenstein Public Relations
Rubenstein Public Relations (RPR) is an award-winning strategic communications firm specializing in high impact media relations and crisis communications for companies operating at the intersection of enterprise, new technology, capital markets, and global industry. Led by industry veteran and brand architect Richard Rubenstein, the firm advises organizations across technology, artificial intelligence, healthcare and life sciences, mining and critical materials, energy, finance, real estate, and other sectors shaping the modern economy. RPR partners with leadership teams to define narratives, elevate visibility, and support key business objectives, including fundraising, transactions, and market expansion. Acting as an extension of its clients’ executive teams, the firm delivers senior-level counsel across tier-one media, social media management, executive positioning and thought leadership, celebrity and influencer engagement, strategic deal negotiation, and high-impact intellectual property initiatives that further amplify brand authority and reach.

RPR has been recognized among the nation’s leading communications firms by Forbes, Newsweek, and UpCity, and has received multiple national and global distinctions for excellence in strategic communications and advisory services. Richard Rubenstein has also been repeatedly recognized among New York’s most influential communications leaders by Schneps Media and PoliticsNY & amNY Metro.

Press Contact:
Stephanie Dallara
Rubenstein Public Relations
sdallara@rubensteinpr.com
+1 212-805-3052